Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alkermes plc (ALKS) vs Liquidia Corporation (LQDA)

Alkermes plc and Liquidia Corporation are both Drug Manufacturers Specialty & Generic companies. Alkermes plc and Liquidia Corporation are of similar size ($6.8B and $6.4B). Liquidia Corporation trades at the lower P/E: 43.6× against 101×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against 10.8%. Liquidia Corporation has the higher net margin (30.7% vs 3.97%) and the higher return on invested capital (121.1% vs 2.76%). Across the 21 metrics below, Liquidia Corporation leads on 13 and Alkermes plc on 8.

Valuation

Metric ALKS LQDA Drug Manufacturers Specialty & Generic median
P/E 101.36 43.59 20.14
P/S 4.09 13.49 2.25
P/B 3.77 31.17 1.90
Price to free cash flow 30.64 40.36 16.54
EV/EBITDA 34.45 35.09 12.29
EV/Sales 4.60 13.25 2.56
Earnings yield 0.99% 2.29% (2.99%)
Free cash flow yield 3.26% 2.48% 0.00%

Profitability

Metric ALKS LQDA Drug Manufacturers Specialty & Generic median
Gross margin 84.56% 92.54% 53.94%
Operating margin 7.03% 37.39% 0.00%
Net margin 3.97% 30.74% 0.00%
Free cash flow margin 13.35% 33.42% 0.00%
Return on equity 3.85% 131.82% (0.40%)
Return on assets 1.99% 35.57% (3.32%)
Return on invested capital 2.76% 121.05% 0.00%

Growth

Metric ALKS LQDA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 10.79% 2,233.65% 10.01%
EPS growth (last fiscal year) (34.10%) 51.81% —
Revenue growth, 5-year CAGR 7.28% 65.24% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALKS LQDA Drug Manufacturers Specialty & Generic median
Debt to equity 0.83 0.90 0.05
Current ratio 2.30 2.31 2.31
Net debt to EBITDA (4.69) (0.01) 0.85

Dividend

Metric ALKS LQDA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ALKS LQDA Drug Manufacturers Specialty & Generic median
Market cap 6.78b 6.36b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack